Emergent BioSolutions | EBS - PE Price to Earnings


Emergent BioSolutions reported 14.4 in PE Price to Earnings for its fiscal quarter ending in September of 2022.





Pe Change Date
Acadia Pharmaceuticals 9.52 1.81 Sep/2026
Akebia Therapeutics 1.63K 1.6K Dec/2025
ALKERMES 262.4 126.59 Sep/2026
Alnylam Pharmaceuticals 13.17 62.47 Sep/2026
Amarin 91.05 88.3 Jun/2023
ANI Pharmaceuticals 15.46 8.81 Sep/2026
BioMarin Pharmaceutical 53.62 32.55 Sep/2026
Emergent BioSolutions 14.4 2.25 Sep/2022
Exelixis 18.43 0.41 Sep/2026
Glaxosmithkline 15.17 0.08 Sep/2026
Ionis Pharmaceuticals 396.15 79.28 Sep/2022
Ironwood Pharmaceuticals 204.24 88.19 Dec/2024
Lexicon Pharmaceuticals 12.44 4.73 Jun/2021
Lonza 34.34 2.58 Dec/2025
Merck 34.36 2.11 Sep/2026
Moderna 27.22 14.51 Jun/2023
Neurocrine Biosciences 83.17 61.07 Sep/2026
Pacira 80.9 45.22 Sep/2026
Pfizer 15.2 3.72 Sep/2026
PTC Therapeutics 8.76 0 Jun/2026
Sanofi 22.34 3.38 Sep/2026
Sarepta Therapeutics 54.75 27.48 Jun/2026
United Therapeutics 19.41 0.26 Sep/2026
Vanda Pharmaceuticals 16.79 7.07 Jun/2023